Correlation Between MorphoSys and Enliven Therapeutics

Can any of the company-specific risk be diversified away by investing in both MorphoSys and Enliven Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MorphoSys and Enliven Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between MorphoSys AG ADR and Enliven Therapeutics, you can compare the effects of market volatilities on MorphoSys and Enliven Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MorphoSys with a short position of Enliven Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of MorphoSys and Enliven Therapeutics.

Diversification Opportunities for MorphoSys and Enliven Therapeutics

0.35

Correlation Coefficient

MorphoSys  Enliven Therapeutics

Weak diversification

The 3 months correlation between MorphoSys and Enliven is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding MorphoSys AG ADR and Enliven Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enliven Therapeutics and MorphoSys is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MorphoSys AG ADR are associated (or correlated) with Enliven Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enliven Therapeutics has no effect on the direction of MorphoSys i.e., MorphoSys and Enliven Therapeutics go up and down completely randomly.

Pair Corralation between MorphoSys and Enliven Therapeutics

Considering the 90-day investment horizon MorphoSys AG ADR is expected to under-perform the Enliven Therapeutics. In addition to that, MorphoSys is 5.83 times more volatile than Enliven Therapeutics. It trades about -0.18 of its total potential returns per unit of risk. Enliven Therapeutics is currently generating about 0.01 per unit of volatility. If you would invest  2,270  in Enliven Therapeutics on September 29, 2024 and sell it today you would lose (33.00) from holding Enliven Therapeutics or give up 1.45% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	22.22%
Values	Daily Returns

MorphoSys AG ADR  vs.  Enliven Therapeutics

MorphoSys AG ADR

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days MorphoSys AG ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, MorphoSys is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

Enliven Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Enliven Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with MorphoSys and Enliven Therapeutics

The main advantage of trading using opposite MorphoSys and Enliven Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MorphoSys position performs unexpectedly, Enliven Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will offset losses from the drop in Enliven Therapeutics' long position.

The idea behind MorphoSys AG ADR and Enliven Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.